What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists — a class of medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have transformed the medical management of type 2 diabetes and obesity. By mimicking glucagon-like peptide-1, a naturally occurring gut hormone that stimulates insulin release, slows gastric emptying, and signals satiety to the brain, these medications produce substantial, sustained weight loss with significant metabolic benefits. They also produce a predictable set of side effects that most patients will experience to some degree, particularly during the dose titration period.
Understanding these side effects before they occur — and knowing practical management strategies — dramatically improves patient compliance and outcomes. The majority of GLP-1 side effects are transient, dose-dependent, and manageable with simple modifications to timing, food choices, and hydration.
Want to talk it through with our team?
Book a free 15-minute video consult. Start for $247 — includes your first doctor visit. No membership.
The Most Common GLP-1 Side Effects
Nausea
Nausea is the most frequently reported side effect of semaglutide and tirzepatide, occurring in 30–40% of patients during dose escalation. The mechanism is straightforward: GLP-1 receptors in the brainstem (area postrema) are stimulated by the medication, triggering nausea signals. The slowing of gastric emptying (a desired therapeutic effect for weight loss) also contributes — food stays in the stomach longer, creating a sensation of fullness that can progress to nausea when meals are too large or eaten too quickly.
Management:
- Eat smaller portions than usual, particularly during the first 4–8 weeks
- Eat slowly — the satiety signal from GLP-1 is exaggerated; eating past the first sense of fullness is a primary nausea trigger
- Avoid high-fat meals for the first several weeks — fat slows gastric emptying independently, compounding the GLP-1 effect
- Inject at night before bed rather than in the morning — peak medication levels coincide with sleep when nausea is most tolerable
- Ginger tea, ginger chews, or over-the-counter ondansetron (Zofran) for significant episodes
- If nausea is severe and persistent beyond the first 2 weeks at a new dose, slow the titration schedule rather than abandoning the medication
Vomiting
Vomiting is less common than nausea but occurs in 10–20% of patients, typically as an extension of significant nausea. It is more common with tirzepatide than semaglutide in some trial data. The same management principles apply — eat smaller meals, slow the titration, inject before bed — but vomiting that persists beyond brief episodes or causes inability to eat or drink requires evaluation to rule out gastroparesis, a rare but known complication of GLP-1 therapy at higher doses in susceptible patients.
Diarrhea
Diarrhea affects approximately 15–25% of patients, more commonly with tirzepatide. The mechanism involves GLP-1 receptor stimulation in the intestinal tract altering motility. It typically occurs in the first several weeks after a dose increase.
Management:
- Increase fluid intake — dehydration risk is real when diarrhea is persistent
- Reduce dietary fiber temporarily during peak episodes
- Loperamide (Imodium) for significant episodes
- If diarrhea is prolonged or severe, temporarily reducing dose before the next scheduled escalation is appropriate
Constipation
Paradoxically, constipation is also a frequent GLP-1 side effect, particularly with semaglutide. Some patients transition between diarrhea and constipation; others experience predominantly one or the other. The mechanism is reduced GI motility from gastric emptying delay.
Management:
- Increase daily water intake to at least 2–3 liters
- Increase dietary fiber gradually (too fast increases gas and discomfort)
- Osmotic laxatives (polyethylene glycol, MiraLax) are well-tolerated and effective
- Prunes, psyllium husk, and magnesium citrate are all reasonable adjuncts
Fatigue
Mild fatigue is reported by 10–15% of patients, typically in the first several weeks. This partly reflects reduced caloric intake (the medication’s desired effect) and partly reflects the metabolic adjustment period. Ensuring adequate protein intake (at least 0.8–1.2g per pound of lean body mass daily) and maintaining physical activity within tolerance helps manage fatigue. Fatigue that is severe or persistent past 4–6 weeks warrants evaluation — particularly thyroid function, iron status, and electrolytes.
Injection Site Reactions
Mild redness, itching, or minor bruising at the injection site occurs in 5–10% of patients. Rotating injection sites (abdomen, thigh, upper arm) minimizes local reactions. Warming the medication to room temperature before injection reduces injection site discomfort.
Less Common but Important Side Effects
Muscle Loss
GLP-1 medications reduce overall caloric intake significantly. Without intentional protein intake and resistance exercise, a substantial proportion of weight lost can be lean muscle mass rather than fat. Clinical trial data suggests 25–40% of weight lost on GLP-1 therapy without exercise is muscle. This is clinically significant — muscle loss impairs long-term metabolic rate, increases fall risk, and reduces functional capacity.
Management: protein intake of at least 1g per pound of lean body mass daily, combined with resistance training (2–4 sessions per week) throughout the GLP-1 program, is the standard recommendation from sports medicine and obesity medicine specialists. This is not optional — muscle preservation is a core component of the program.
Gastroparesis (Delayed Gastric Emptying)
Severe, persistent gastric emptying delay — presenting as prolonged nausea, early satiety, vomiting of undigested food, and significant abdominal bloating — is a rare but serious complication of GLP-1 therapy at higher doses in susceptible patients. Risk factors include prior vagal nerve dysfunction, prior bariatric surgery, and autonomic neuropathy. Patients with a history of gastroparesis should not use GLP-1 agonists.
Pancreatitis Risk
GLP-1 medications carry a small increase in pancreatitis risk — the FDA label carries a warning. Presenting symptoms include severe, constant abdominal pain radiating to the back, often with nausea and vomiting. Any patient on a GLP-1 medication experiencing severe abdominal pain should stop the medication and seek immediate medical evaluation. Patients with a prior history of pancreatitis are generally not candidates for GLP-1 therapy.
Managing GLP-1 Side Effects: The Key Principle
The most important principle in GLP-1 side effect management is titration. The vast majority of GI side effects are dose-dependent and occur most intensely at the beginning of a new dose level. Slowing the titration — holding at a dose for longer than the standard protocol when side effects are significant — dramatically reduces the severity of the GI side effect burden without meaningfully compromising long-term weight loss outcomes. Patients who abandon GLP-1 therapy due to side effects overwhelmingly do so in the first 4–8 weeks; the GI side effect burden decreases substantially after this initial adaptation period for most patients.
How it works
From your first call to medication at your door.
- AFree 15-minute video consult. We go over your goals, answer your questions, and confirm we can treat you in your state.
- BStart for $247, which includes your first doctor visit.
- CLab work: free with insurance at Quest or any other lab. Book your Quest visit in your patient portal, or take our lab order form to any lab that takes your insurance.
- DDoctor visit: once results are back, meet by video with a dedicated hormone therapy specialist (PAs, NPs and doctors on staff) to review labs and plan medication or therapy.
- EMedication shipped to your door. We bill you for the medication and ship it to your house. See medication prices
What it costs
- No monthly fee, no membership, no commitment.
- $97 per visit, only when needed.
- Prescriptions need lab work and a video visit at least every 90 days.
- Most new patients are seen every 30 days at first.